CLAIMS

1. The use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate and solvate thereof in the manufacture of a medicament for the treatment of acute exacerbations of chronic obstructive pulmonary disease.

2. The use of claim 1, wherein the 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methyl-benzamide or a pharmaceutically acceptable salt, hydrate and solvate thereof is in the form of a single dose.

3. The use according to claim 2, wherein the single dose comprises 50 to 100 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate and solvate thereof.

4. The use according to claim 2, wherein the single dose comprises 60 to 90 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate and solvate thereof.

5. The use according to claim 2, wherein the single dose comprises 75 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable salt, hydrate and solvate thereof.

6. The use according to claim 2, wherein the single dose comprises 75 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methylbenzamide in its free form.

7. The use according to claim 1, wherein the medicament is for oral administration.

8. The use according to claim 7, wherein the composition contains 75 mg of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-l-yl]-N-cyclopropyl-4-methyl-benzamide or a pharmaceutically acceptable salt, hydrate and solvate thereof.

9. The use according to claim 7, in the form of a tablet.